STEM-01. PREDICTABLE AND DISTINCT MECHANISMS DRIVE DE NOVO VS. ACQUIRED RESISTANCE TO SMO/SHH INHIBITORS IN SHH MEDULLOBLASTOMAS

Emergence of therapy resistance greatly reduces long-term utility of effective targeted therapies, including SMO/SHH pathway inhibitors. SHH signaling is elevated in ~25% of human medulloblastomas (MB), and FDA approved SMOi (to treat basal cell carcinoma (BCC)) are currently in clinical trials for...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Chen, Yaohui, George, Joshy, Abdelfattah, Nourhan, Yamamoto, Keiko, Rybinski, Brad, Adamson, Scott, Chuang, Jeff, Yun, Kyuson
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Stem Cells
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477217/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz036.208
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars